AU2001271973A1 - Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis - Google Patents
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesisInfo
- Publication number
- AU2001271973A1 AU2001271973A1 AU2001271973A AU2001271973A AU2001271973A1 AU 2001271973 A1 AU2001271973 A1 AU 2001271973A1 AU 2001271973 A AU2001271973 A AU 2001271973A AU 2001271973 A AU2001271973 A AU 2001271973A AU 2001271973 A1 AU2001271973 A1 AU 2001271973A1
- Authority
- AU
- Australia
- Prior art keywords
- diagnosis
- compositions
- treatment
- methods
- disorders involving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (73)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21955600P | 2000-07-20 | 2000-07-20 | |
US60/219,556 | 2000-07-20 | ||
US22062400P | 2000-07-25 | 2000-07-25 | |
US22066400P | 2000-07-25 | 2000-07-25 | |
US60/220,664 | 2000-07-25 | ||
US60/220,624 | 2000-07-25 | ||
AU63910/00 | 2000-07-28 | ||
PCT/US2000/020710 WO2001009327A2 (en) | 1999-07-28 | 2000-07-28 | Method of preventing the injury or death of retinal cells and treating ocular diseases |
US22269500P | 2000-08-02 | 2000-08-02 | |
US60/222,695 | 2000-08-02 | ||
US09/643,657 US6642024B1 (en) | 1998-01-29 | 2000-08-17 | Guanylate-binding protein |
US09/643,657 | 2000-08-17 | ||
AU70793/00 | 2000-08-23 | ||
PCT/US2000/023522 WO2001016319A2 (en) | 1999-08-31 | 2000-08-23 | Compositions and methods for the treatment of immune related diseases |
AU75730/00 | 2000-08-24 | ||
PCT/US2000/023328 WO2001016318A2 (en) | 1999-09-01 | 2000-08-24 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US23097800P | 2000-09-07 | 2000-09-07 | |
US60/230,978 | 2000-09-07 | ||
US60/000,000 | 2000-09-15 | ||
US66535000A | 2000-09-18 | 2000-09-18 | |
US66461000A | 2000-09-18 | 2000-09-18 | |
US09/664,610 | 2000-09-18 | ||
US09/665,350 | 2000-09-18 | ||
US24292200P | 2000-10-24 | 2000-10-24 | |
US60/242,922 | 2000-10-24 | ||
US70923800A | 2000-11-08 | 2000-11-08 | |
PCT/US2000/030952 WO2001049715A2 (en) | 2000-01-06 | 2000-11-08 | Methods and compositions for inhibiting neoplastic cell growth |
AU19167/01 | 2000-11-08 | ||
US09/709,238 | 2000-11-08 | ||
AU34346/01 | 2000-11-10 | ||
PCT/US2000/030873 WO2001040465A2 (en) | 1999-11-30 | 2000-11-10 | Compositions and methods for the treatment of immune related diseases |
AU20554/01 | 2000-12-01 | ||
PCT/US2000/032678 WO2001040466A2 (en) | 1999-12-01 | 2000-12-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US09/747,259 US6569645B2 (en) | 1999-05-14 | 2000-12-20 | IL-17 homologous polypeptides and therapeutic uses thereof |
AU25909/01 | 2000-12-20 | ||
US09/747,259 | 2000-12-20 | ||
PCT/US2000/034956 WO2001046420A2 (en) | 1999-12-23 | 2000-12-20 | Il-17 and il-17r homologous polypeptides and therapeutic uses thereof |
US09/767,609 | 2001-01-22 | ||
US09/767,609 US20020042367A1 (en) | 1997-11-25 | 2001-01-22 | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders |
US79649801A | 2001-02-28 | 2001-02-28 | |
US09/796,498 | 2001-02-28 | ||
AU2001268028 | 2001-02-28 | ||
PCT/US2001/006520 WO2001068848A2 (en) | 2000-03-01 | 2001-02-28 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2001255168 | 2001-03-01 | ||
PCT/US2001/006666 WO2001066740A2 (en) | 2000-03-03 | 2001-03-01 | Compositions and methods for the treatment of immune related diseases |
US80270601A | 2001-03-09 | 2001-03-09 | |
US09/802,706 | 2001-03-09 | ||
US80868901A | 2001-03-14 | 2001-03-14 | |
US09/808,689 | 2001-03-14 | ||
US09/816,744 | 2001-03-22 | ||
US09/816,744 US6579520B2 (en) | 1998-05-15 | 2001-03-22 | IL-17 related mammalian cytokine polypeptides (IL-17E) |
US09/828,366 | 2001-04-05 | ||
US09/828,366 US20020010137A1 (en) | 1997-09-18 | 2001-04-05 | Methods and compositions for inhibiting neoplastic cell growth |
US09/854,208 | 2001-05-10 | ||
US09/854,280 US7115398B2 (en) | 1998-05-15 | 2001-05-10 | IL-17 homologous polypeptides and therapeutic uses thereof |
US09/854,208 US7217412B2 (en) | 1998-05-15 | 2001-05-10 | IL-17C related mammalian cytokine polypeptides |
US09/854,280 | 2001-05-10 | ||
US09/866,034 US20030170864A1 (en) | 2000-05-30 | 2001-05-25 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US09/866,028 US6642360B2 (en) | 1997-12-03 | 2001-05-25 | Secreted polypeptides that stimulate release of proteoglycans from cartilage |
US09/866,028 | 2001-05-25 | ||
US09/866,034 | 2001-05-25 | ||
PCT/US2001/017092 WO2001092331A2 (en) | 2000-05-30 | 2001-05-25 | Compositions and methods for the treatment of immune related diseases |
AU2001265019 | 2001-05-25 | ||
US09/870,574 | 2001-05-30 | ||
US09/870,574 US6551799B2 (en) | 1999-12-07 | 2001-05-30 | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
PCT/US2001/017443 WO2002016611A2 (en) | 2000-08-24 | 2001-05-30 | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
AU2001268108 | 2001-05-30 | ||
AU2001265311 | 2001-06-01 | ||
PCT/US2001/017800 WO2001093983A1 (en) | 2000-06-02 | 2001-06-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2001278852 | 2001-06-20 | ||
PCT/US2001/019692 WO2002000690A2 (en) | 2000-06-23 | 2001-06-20 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
USPCT/US01/00000 | 2001-06-28 | ||
PCT/US2001/021735 WO2002008284A2 (en) | 2000-07-20 | 2001-07-09 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001271973A1 true AU2001271973A1 (en) | 2002-02-05 |
Family
ID=56290165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001271973A Abandoned AU2001271973A1 (en) | 2000-07-20 | 2001-07-09 | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1309685A2 (en) |
JP (5) | JP2004516013A (en) |
AU (1) | AU2001271973A1 (en) |
CA (1) | CA2416538A1 (en) |
WO (1) | WO2002008284A2 (en) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2286856T3 (en) | 1997-09-12 | 2007-12-01 | Biogen Idec Ma Inc. | TRAIN RICH RECEIVERS IN CISTEINA. |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) * | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
AU740405B2 (en) | 1998-05-15 | 2001-11-01 | Genentech Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US7465785B2 (en) | 1999-03-08 | 2008-12-16 | Genentech, Inc. | Polypeptide encoded by a nucleic acid over-expressed in melanoma |
US20030119113A1 (en) | 1999-07-20 | 2003-06-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1623993A3 (en) * | 1999-09-01 | 2006-06-07 | Genetech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP2290081A3 (en) * | 1999-12-23 | 2012-08-01 | Genentech, Inc. | IL-17 homologous polypeptide and therapeutic uses thereof |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
CA2406884C (en) | 2000-04-21 | 2009-02-17 | Fuso Pharmaceutical Industries, Ltd. | Novel collectins |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP2792747A1 (en) * | 2000-06-23 | 2014-10-22 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
JP2004506413A (en) * | 2000-06-23 | 2004-03-04 | ジェネンテック・インコーポレーテッド | Compositions and methods for diagnosis and treatment of diseases involving angiogenesis |
CA2648048A1 (en) * | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US7115415B2 (en) | 2000-09-15 | 2006-10-03 | Genentech, Inc. | PRO9821 nucleic acids |
US6630325B1 (en) * | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
WO2002036625A2 (en) | 2000-11-03 | 2002-05-10 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
WO2002040654A2 (en) | 2000-11-14 | 2002-05-23 | Bristol-Myers Squibb Company | A human serpin secreted from lymphoid cells lsi-01 |
US7250495B2 (en) | 2001-06-20 | 2007-07-31 | Genentech, Inc. | PRO20044 polypeptides |
EP1530590A2 (en) * | 2002-03-22 | 2005-05-18 | Bioxell S.p.a. | Triggering receptors expressed on myeloid cells (trem)-4 and -5 and uses thereof |
JPWO2003083114A1 (en) * | 2002-03-28 | 2005-08-04 | アステラス製薬株式会社 | Angiopoietin-related growth factor |
JP2005536190A (en) * | 2002-04-16 | 2005-12-02 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2003261911A1 (en) * | 2002-09-04 | 2004-03-29 | Takeda Pharmaceutical Company Limited | Use of disease-associated gene |
EP2116616A3 (en) * | 2002-09-11 | 2010-03-17 | Genentech, Inc. | Genes differentially expressed in activated T cells and uses thereof |
US20070042945A1 (en) * | 2002-09-25 | 2007-02-22 | Genentech, Inc. | Nouvelles compositions et methods de traitement du psoriasis |
KR101118340B1 (en) | 2003-03-12 | 2012-04-12 | 제넨테크, 인크. | Use of bv8 and/or eg-vegf to promote hematopoiesis |
MX341074B (en) | 2003-07-08 | 2016-08-05 | Genentech Inc | Il-17 a/f heterologous polypeptides and therapeutic uses thereof. |
US20100031378A1 (en) | 2008-08-04 | 2010-02-04 | Edwards Joel A | Novel gene disruptions, compositions and methods relating thereto |
AU2005249377A1 (en) | 2004-04-14 | 2005-12-15 | Genentech, Inc. | Compositions and methods comprising an EGFL7 antagonist for modulating vascular development |
EP1781682B1 (en) | 2004-06-24 | 2013-03-13 | Mayo Foundation For Medical Education And Research | B7-h5, a costimulatory polypeptide |
ZA200610273B (en) | 2004-07-02 | 2008-06-25 | Genentech Inc | Compositions and methods for treatment of non-hodgkin's lymphoma |
CA2576193A1 (en) | 2004-08-03 | 2006-02-16 | Biogen Idec Ma Inc. | Taj in neuronal function |
US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
BRPI0619657A2 (en) | 2005-11-04 | 2011-11-08 | Genentech Inc | methods of preventing or ameliorating eye disease, using a complement inhibitor, using a specific siren for a complement system protein and using a nucleic acid encoding a complement system inhibitor |
EP2471818A1 (en) | 2006-11-02 | 2012-07-04 | Genentech, Inc. | Humanized anti-factor D antibodies and uses thereof |
AR066660A1 (en) | 2007-05-23 | 2009-09-02 | Genentech Inc | PREVENTION AND TREATMENT OF EYE CONDITIONS ASSOCIATED WITH THEIR COMPLEMENT |
WO2009070243A2 (en) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
CR20170001A (en) | 2008-04-28 | 2017-08-10 | Genentech Inc | ANTI FACTOR D HUMANIZED ANTIBODIES |
MX2010012090A (en) | 2008-05-05 | 2011-04-11 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof. |
KR101690590B1 (en) | 2008-05-06 | 2016-12-28 | 제넨테크, 인크. | AFFINITY MATURED CRIg VARIANTS |
PL2398902T3 (en) | 2009-02-20 | 2024-02-26 | Astellas Pharma Inc. | Methods and compositions for diagnosis and treatment of cancer |
CA2759848C (en) | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
MX2011010570A (en) | 2009-05-08 | 2011-10-19 | Genentech Inc | Humanized anti-egfl7 antibodies and methods using same. |
AT508569A1 (en) | 2009-07-23 | 2011-02-15 | Affiris Ag | PHARMACEUTICAL COMPOUND |
CN111875703A (en) | 2009-11-11 | 2020-11-03 | 安斯泰来制药股份有限公司 | Antibodies specific for claudin 6(CLDN6) |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
ES2565063T3 (en) | 2011-05-13 | 2016-03-31 | Ganymed Pharmaceuticals Ag | Antibodies for the treatment of cancer that expresses claudin 6 |
MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
NZ630484A (en) | 2012-11-28 | 2017-04-28 | Ngm Biopharmaceuticals Inc | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
JP6809789B2 (en) * | 2013-01-17 | 2021-01-06 | メディツィーニシェ・ホーホシューレ・ハノーファーMedizinische Hochschule Hannover | Factor 1 and Factor 2 proteins for use in the treatment or prevention of disease, and their inhibitors |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
WO2015023596A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | Compositions and method for treating complement-associated conditions |
CN105828878A (en) | 2013-10-28 | 2016-08-03 | 恩格姆生物制药公司 | Cancer models and associated methods |
RU2701434C2 (en) | 2014-01-24 | 2019-09-26 | Нгм Биофармасьютикалс, Инк. | Binding proteins and methods for use thereof |
CN106536561A (en) | 2014-05-01 | 2017-03-22 | 豪夫迈·罗氏有限公司 | Anti-factor D antibody variants and uses thereof |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
IL251834B2 (en) | 2014-10-23 | 2023-09-01 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
CN108289951A (en) | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody and conjugate |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
EP3377090B1 (en) | 2015-11-09 | 2021-04-07 | NGM Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
GB201906052D0 (en) * | 2019-04-30 | 2019-06-12 | Int Centre For Genetic Engineering And Biotechnology | Proteins with cardioprotective activity |
JP7064179B2 (en) | 2020-11-30 | 2022-05-10 | 富士電機株式会社 | Moisture adsorbent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999046281A2 (en) * | 1998-03-10 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
WO1999010363A1 (en) * | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | 29 human secreted proteins |
CA2322711A1 (en) * | 1998-02-27 | 1999-09-02 | Sagami Chemical Research Center | Human proteins having transmembrane domains and dnas encoding these proteins |
EP1068307A1 (en) * | 1998-03-31 | 2001-01-17 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
MXPA01002546A (en) * | 1998-09-14 | 2004-06-11 | Genentech Inc | Promotion or inhibition of angiogenesis and cardiovascularization. |
JP3695642B2 (en) * | 1998-12-01 | 2005-09-14 | ジェネンテック・インコーポレーテッド | Promotion or inhibition of angiogenesis and cardiovascularization |
KR20030002292A (en) * | 1999-03-08 | 2003-01-08 | 제넨테크, 인크. | Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same |
AU2399300A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
KR100543857B1 (en) * | 1999-09-01 | 2006-01-23 | 제넨테크, 인크. | Promotion or Inhibition of Angiogenesis and Cardiovascularization |
JP2004506413A (en) * | 2000-06-23 | 2004-03-04 | ジェネンテック・インコーポレーテッド | Compositions and methods for diagnosis and treatment of diseases involving angiogenesis |
-
2001
- 2001-07-09 JP JP2002514188A patent/JP2004516013A/en not_active Withdrawn
- 2001-07-09 CA CA002416538A patent/CA2416538A1/en not_active Abandoned
- 2001-07-09 EP EP01951036A patent/EP1309685A2/en not_active Withdrawn
- 2001-07-09 WO PCT/US2001/021735 patent/WO2002008284A2/en active Search and Examination
- 2001-07-09 AU AU2001271973A patent/AU2001271973A1/en not_active Abandoned
-
2008
- 2008-07-29 JP JP2008194764A patent/JP2009039119A/en not_active Withdrawn
- 2008-07-29 JP JP2008194678A patent/JP2009039117A/en not_active Withdrawn
- 2008-07-29 JP JP2008194721A patent/JP2009039118A/en not_active Withdrawn
-
2011
- 2011-08-08 JP JP2011173336A patent/JP6033531B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002008284A2 (en) | 2002-01-31 |
CA2416538A1 (en) | 2002-01-31 |
EP1309685A2 (en) | 2003-05-14 |
JP2012005493A (en) | 2012-01-12 |
WO2002008284A3 (en) | 2003-03-13 |
JP2004516013A (en) | 2004-06-03 |
JP2009039119A (en) | 2009-02-26 |
JP2009039118A (en) | 2009-02-26 |
JP6033531B2 (en) | 2016-11-30 |
JP2009039117A (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001271973A1 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
AU2001278852A1 (en) | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis | |
AU7722600A (en) | Compositions and methods for the diagnosis and treatment of immune disorders | |
WO2003034984A9 (en) | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders | |
AU2002252373A1 (en) | Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders | |
WO2002086502A8 (en) | Methods for the diagnosis and treatment of bone disorders | |
AU2003213787A1 (en) | Compositions and methods for the treatment of anorectal disorders | |
ZA200301204B (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU5309600A (en) | Compositions and methods for the treatment and diagnosis of immune disorders | |
AUPR101600A0 (en) | Compositions and methods for diagnosis and treatment of cardiovascular disorders | |
AU3632600A (en) | Compositions and methods for the treatment of immune related diseases | |
AU2001256855A1 (en) | Preparation for the prevention and treatment of ocular disorders | |
AU8678501A (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2001257406A1 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941 | |
AU4228000A (en) | Methods and compositions for the treatment and prevention of lung disease | |
AU3434601A (en) | Compositions and methods for the treatment of immune related diseases | |
AU2001283199A1 (en) | Methods and compositions for the diagnosis and treatment of brown adipose cell disorders | |
AU2001255730A1 (en) | Methods and compositions for the treatment of cardiac indications | |
AU2002258798A1 (en) | Methods for the treatment of hepatic disorders | |
EP1315499A4 (en) | Compositions and methods for the treatment of anorectal disorders | |
AU2002210763A1 (en) | Use of 1-ebio in the treatment of bipolar disorders | |
AU4225500A (en) | Methods and compositions for the treatment and prevention of lung disease | |
AU2001255168A1 (en) | Compositions and methods for the treatment of immune related diseases | |
AU2002348324A1 (en) | Methods and compositions for the treatment and diagnosis of pain disorders using 46566 | |
AU2215099A (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |